Patents by Inventor Ronald R. Tuttle

Ronald R. Tuttle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth promotion
    Patent number: 4849453
    Abstract: .beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: July 18, 1989
    Assignee: Eli Lilly and Company
    Inventors: David B. Anderson, Klaus K. Schmiegel, Edward L. Veenhuizen, Ronald R. Tuttle
  • Glucuronic acid derivatives of opioid antagonists
    Patent number: 4774230
    Abstract: Intestine-specific delivery of an opioid antagonist can be accomplished without substantial central nervous system effects by administering the antagonist orally in the form of the glucuronide derivative.
    Type: Grant
    Filed: March 26, 1988
    Date of Patent: September 27, 1988
    Assignee: Ivax Laboratories, Inc.
    Inventors: Ronald R. Tuttle, Ross Dixon, Maciej M. Smulkowski
  • Orally effective inotropic compounds
    Patent number: 4562206
    Abstract: A method for increasing cardiac contractility in a warm-blooded animal suffering from acutely depressed cardiac contractility which comprises administering to said animal an effective amount of a compound of the formula ##STR1## wherein R is hydrogen or isobutyrate, or a pharmaceutically acceptable acid addition salt thereof.
    Type: Grant
    Filed: March 8, 1984
    Date of Patent: December 31, 1985
    Assignee: Key Pharmaceuticals, Inc.
    Inventor: Ronald R. Tuttle
  • Senile dementia treatment
    Patent number: 4511570
    Abstract: A method is provided for orally treating a patient suffering from senile dementia which comprises the periodic oral delivery of a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to said patient, whereby the patient tends to reduce his food intake. Also provided is an oral sustained release dosage unit form suitable for treating a patient suffering from obesity which permits a prolonged interval between administration to said patient, said oral dosage unit formulation comprising a plurality of granules which together constitute a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to provide a sustained action over said prolonged interval, said plurality of granules each comprising a polymeric matrix to permit a substantially even release of said 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to permit the necessary sustained release over the prolonged period of time.
    Type: Grant
    Filed: March 28, 1983
    Date of Patent: April 16, 1985
    Assignee: Key Pharmaceuticals, Inc.
    Inventor: Ronald R. Tuttle
  • Hyperkinetic child treatment agent
    Patent number: 4483860
    Abstract: A method of orally treating a child having a tendency to be overactive to the extent of requiring an external control which comprises orally administering to said child a pharmaceutically effective amount of (-)-17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxymorpinan-6-one to said patient, whereby the attention span of the child lengthened. An oral sustained release dosage unit containing (-)-17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxymorpinan-6-one is disclosed also.
    Type: Grant
    Filed: September 12, 1983
    Date of Patent: November 20, 1984
    Assignee: Key Pharmaceuticals, Inc.
    Inventor: Ronald R. Tuttle
  • Hyperkinetic child treatment agent
    Patent number: 4454142
    Abstract: Provided is a method of orally treating a child having a tendency to be overactive to the extent of requiring an external control which comprises orally administering to said child a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to said patient, whereby the patient tends to reduce his food intake.
    Type: Grant
    Filed: May 26, 1983
    Date of Patent: June 12, 1984
    Assignee: Key Pharmaceuticals, Inc.
    Inventor: Ronald R. Tuttle
  • 3,4-Dih ydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
    Patent number: 4425336
    Abstract: Cardiac contractility agents are provided which are 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamin e cyclodextrin complexes.
    Type: Grant
    Filed: May 24, 1982
    Date of Patent: January 10, 1984
    Assignee: Key Pharmaceuticals, Inc.
    Inventor: Ronald R. Tuttle
  • 3,4-Di -isobutyryloxy-N-?3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phene thylamine cyclodextrin complexes
    Patent number: 4424209
    Abstract: Cardiac contractility agents are provided which are 3,4-di-isobutyryloxy-N-?3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta- phenethylamine, preferably orally deliverable forms which are cyclodextrin complexes.
    Type: Grant
    Filed: June 21, 1982
    Date of Patent: January 3, 1984
    Assignee: Key Pharmaceuticals, Inc.
    Inventor: Ronald R. Tuttle
  • Method for increasing cardiac contractility
    Patent number: 3987200
    Abstract: N-Mono or dihydroxyphenylalkyl dopamine derivatives and salts thereof are inotropic agents useful in a method for treatment of acutely depressed cardiac insufficiency.
    Type: Grant
    Filed: January 15, 1975
    Date of Patent: October 19, 1976
    Assignee: Eli Lilly and Company
    Inventors: Ronald R. Tuttle, Jack Mills